AzTrials
AzTrials

Duchenne Muscular Dystrophy (DMD)Phase 3PROMOVINCT02255552

Study of Eteplirsen in DMD Patients

A Phase 3 study testing eteplirsen in people with Duchenne Muscular Dystrophy (DMD), run by Sarepta Therapeutics, Inc. at 37 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety… Read more about this study

Who is it for?
Ages 7 to 16 years, men only
Conditions the study is for
Duchenne Muscular Dystrophy (DMD)
What is being tested?
eteplirsen
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
109 participants
Where
37 sitesUnited States
Study dates
17 Nov 2014to 14 Jun 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 16 years
  • Men only
  • No healthy volunteers
  • Child

Who may be able to join

  • Male 7-16 years old
  • Diagnosed with DMD, genotypically confirmed
  • Stable dose of corticosteroids for at least 24 weeks
  • Have intact right and left alternative upper muscle groups
  • Mean 6MWT greater than 300m (primary analysis on 300 to 450 meters)
  • Stable pulmonary and cardiac function: predicted FVC equal to or greater than 50% and LVEF of greater than 50%

Who cannot join

  • Previous treatment with drisapersen or any other RNA antisense agent or any gene therapy within the last 6 months
  • Participation in any other DMD interventional clinical study within 12 weeks
  • Major surgery within 3 months
  • Presence of other clinically significant illness
  • Major change in the physical therapy regime within 3 months
  • Other inclusion/exclusion criteria apply.

Trial locations and contacts

37 sites in 1 country.

37 sites in 1 country

United States37 sites
  • Rare Disease Research Center

    Atlanta, Georgia, 30318

  • Emory University

    Atlanta, Georgia, 30324

  • Children's Hospital Colorado

    Aurora, Colorado, 80045

  • Kennedy Krieger Institute

    Baltimore, Maryland, 21205

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

  • Children's Hospital Boston

    Boston, Massachusetts, 02115

  • Levine Childrens Hospital, Carolinas Medical Center

    Charlotte, North Carolina, 28207

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611

  • Cincinnati Children's Hospital Medical Center (CCHMC)

    Cincinnati, Ohio, 45229

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205

  • The University of Texas Southwestern Medical Center

    Dallas, Texas, 75390

  • Children's Hospital of Michigan

    Detroit, Michigan, 48201

  • The University of Florida, Powell Gene Therapy Center

    Gainesville, Florida, 32610

  • NW FL Clinical Research Group, LLC

    Gulf Breeze, Florida, 32561

  • Connecticut Children's Medical Center

    Hartford, Connecticut, 06106

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania, 17033

  • Texas Children's Hospital

    Houston, Texas, 77030

  • University of Iowa Children's Hospital

    Iowa City, Iowa, 52242

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

  • David Geffen School of Medicine at UCLA

    Los Angeles, California, 90095

  • University of Minnesota

    Minneapolis, Minnesota, 55455

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

  • Columbia University Medical Center

    New York, New York, 10032

  • Nemours Children's Hospital

    Orlando, Florida, 32827

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

  • Neuromuscular Research Center

    Phoenix, Arizona, 85028

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania, 15224

  • Shriners Hospital for Children

    Portland, Oregon, 97239

  • University of Rochester Clinical Research Center

    Rochester, New York, 14642

  • University of California, Davis Medical Center

    Sacramento, California, 95817

  • University of Utah

    Salt Lake City, Utah, 84132

  • Rady Children's Hospital, U.C. San Diego

    San Diego, California, 92130

  • Seattle Children's Hospital

    Seattle, Washington, 98105

  • St. Louis Children's Hospital

    St Louis, Missouri, 63110

  • Stanford University School of Medicine/Medical Center

    Stanford, California, 94305

  • Children's National Health System

    Washington D.C., District of Columbia, 20010

Other trials in United States

About this study

Official title: An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy

The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).

Read the detailed description

This is an open-label, multi-center study to evaluate the efficacy and safety of eteplirsen in patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to exon 51 skipping (treated group), with a concurrent control arm of DMD patients not amenable to exon 51 skipping (untreated group). Following primary efficacy endpoints, dosing will continue to week 144 to evaluate the long term effects of eteplirsen.

Patients in the treated group will receive once weekly intravenous (IV) infusions of 30 mg/kg Eteplirsen for 96 weeks, followed by a safety extension (not to exceed 48 weeks). Patients in the untreated group will not receive treatment.

Clinical efficacy will be assessed at regularly scheduled study visits, including functional tests such as the six minute walk test. Patients in the treated group will undergo a muscle biopsy at Baseline and a second muscle biopsy over the course of the study. Patients in the untreated group will not undergo muscle biopsy.

Safety, including adverse event monitoring and routine laboratory assessments, will be continuously monitored for all patients.

Being tested
eteplirsen
Keywords
DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51
Medical subject headings
Muscular Dystrophy, Duchenne

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • eteplirsenDrug

    Also called AVI-4658, EXONDYS 51®

    Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).

Study groups in NCT02255552
Study groupRoleWhat they receive
Treated GroupExperimentalApproximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Receives: Drug: eteplirsen
Untreated GroupNo interventionApproximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96

    6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 96 was reported.

    Measured: Baseline, Week 96

Secondary outcomes (6)
  1. Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 96

    Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.

    Measured: Baseline, Week 96

  2. Number of Participants Having Ability to Rise Independently From the Floor Determined Based on North Star Ambulatory Assessment (NSAA) at Week 96

    NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. For all activities, participants were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. Number of participants having ability to rise independently from the floor indicated by a NSAA Rise from floor sub score greater than 0 (unable to achieve goal independently) was reported.

    Measured: Week 96

  3. Number of Participants Who Lost Ambulation (LOA) by Week 96

    Number of participants who lost ambulation (LOA) by Week 96 was reported. Participant were considered non-ambulatory if each of the 3 conditions below were met: NSAA walk subscore was "0" (unable to achieve goal independently) on 2 consecutive days within a visit or NSAA was not done due to reason related to non-ambulation; 6MWT was not done with any reason related to permanent non-ambulation; and no later data showing this participant was still ambulatory. This was not required if non ambulatory status occurred at the time of early withdrawal or at the end of Week 96 assessment. NSAA is a 17-item scale to assess the participant's abilities; total score range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.

    Measured: Up to Week 96

  4. Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Weeks 96

    FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry; and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Percent of predicted FVC = (observed value) / (predicted value) * 100%.

    Measured: Baseline, Week 96

  5. Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Scores at Week 96

    NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. Participant were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. NSAA total score was derived by summing the scores for all the individual items and range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.

    Measured: Baseline, Week 96

  6. Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 96

    Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry.

    Measured: Baseline, Week 96

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Oct 2014 (estimated)
  2. Study start17 Nov 2014
  3. Primary completion14 Jun 2019
  4. Study completion14 Jun 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
109 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02255552
Sponsor's protocol ID
4658-301
Acronym
PROMOVI
Status last verified
Dec 2020
First submitted
25 Sep 2014
Last updated
25 Jan 2021
Data monitoring committee
No
Individual data sharing
No

Publications

  • Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D'Amico A, Bruno C, Vita G, Berardinelli A, Mazzone E, Magri F, Ricci F, Mongini T, Battini R, Bello L, Pegoraro E, Baranello G, Previtali SC, Politano L, Comi GP, Sansone VA, Donati A, Bertini E, Muntoni F, Goemans N, Mercuri E; on behalf on the International DMD group. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS One. 2019 Jun 25;14(6):e0218683. doi: 10.1371/journal.pone.0218683. eCollection 2019.

    PubMed 31237898

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing eteplirsen in people with Duchenne Muscular Dystrophy (DMD), run by Sarepta Therapeutics, Inc. at 37 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 37 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Jul 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96 (time frame: Baseline, Week 96). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02255552, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in